At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,516 enrolled
Drug / intervention
Resolute Zotarolimus-Eluting Coronary Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm
In Brief
A clinical study evaluating Resolute Zotarolimus-Eluting Coronary Stent for Coronary Artery Disease. Completed, enrolled 1,516 participants across 1 site.
Detailed Summary
The objective of the study is to assess the safety and effectiveness of the Resolute Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) of 2.25 mm to 4.2 mm.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
First PostedAug 2008
Primary CompletionJan 2011
Study CompletionMar 2016
TodayJul 2026
First PostedAug 1, 2008
Enrollment StartJul 1, 2008
Primary CompletionJan 1, 2011
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 17.9 years ago
Interventions
Resolute Zotarolimus-Eluting Coronary Stentdevice
Implantation of a Resolute Zotarolimus-Eluting Coronary Stent